TWI809021B - 含有FP促效藥及β阻斷藥的青光眼治療劑 - Google Patents
含有FP促效藥及β阻斷藥的青光眼治療劑 Download PDFInfo
- Publication number
- TWI809021B TWI809021B TW107146169A TW107146169A TWI809021B TW I809021 B TWI809021 B TW I809021B TW 107146169 A TW107146169 A TW 107146169A TW 107146169 A TW107146169 A TW 107146169A TW I809021 B TWI809021 B TW I809021B
- Authority
- TW
- Taiwan
- Prior art keywords
- glaucoma
- agonist
- blocker
- cyclopenta
- hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本發明發現一種有效之青光眼治療法,並提供為醫藥品。
本發明之組合,尤其是4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯與β阻斷藥之組合,相較於各藥劑單劑投予時,具有眼壓降低作用增強且眼壓降低作用持續之效果,故作為青光眼治療劑為有用者。
Description
在本發明之一態樣中,係關於一種青光眼治療劑,該青光眼治療劑含有FP促效藥作為有效成分,並且該FP促效藥係與β阻斷藥組合並投予,上述FP促效藥為下述式表示之化合物。
(式中,所有符號表示與後述者同意義)
青光眼為以發生暫時性或永久性視野缺損、視力降低之視功能障礙為特徴之眼疾患。由於眼房水的循環障礙造成眼房水蓄積,致使眼壓持續地上昇,成為視神經被壓迫之原因。青光眼的治療有效的是降低眼壓,為了降低眼壓,實施例如藥物治療(點眼藥、內服藥、點滴治療)、雷射治療、手術治療。
作為本發明有效成分使用之FP促效藥,已知是作為眼疾患等之預防及/或治療劑有用之醫藥品(參照專利文獻1)。其中,眾所皆知者是4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯之席巴前列素(Sepetaprost;國際一般名)(以下,亦簡稱為化合物A),並且持續地進行作為青光眼之治療藥的開發。
在青光眼之治療現狀中,通常以併用不同眼壓降低機制之藥劑進行,上市的有例如舒而坦(Xalacom)(註冊商標)複方點眼液(拉坦前列素‧滴目露馬來酸酯(Latanoprost‧Timolol maleate)複方)、泰普康(Tapcom)(註冊商標)複方點眼液(泰福前列素‧滴目露馬來酸酯(Tafluprost‧Timolol Maleate)複方)等。
另一方面,於專利文獻1中化合物A記載為實施例16(25),並且揭示β阻斷藥作為用以補齊及/或增強化合物A等對於青光眼之預防及/或治療效果之其他藥物之一例。
[專利文獻1]國際公開第2011/013651號
本發明之課題為發現有效之青光眼治療法,並且提供醫藥品。
本發明人等為了解決上述課題進行深入研究,結果發現藉由將FP促效藥與β阻斷藥組合(以下,亦簡稱為本發明之組合),可解決上述課題。
本發明提供例如下述之實施態樣。
[1]一種青光眼或高眼壓症之治療劑,為含有FP促效藥作為有效成分,並且該FP促效藥係與β阻斷藥或其藥學上容許之鹽組合並投予,上述FP促效藥為4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯;[2]如上述[1]所述之劑,其中,該β阻斷藥為滴目露(Timolol)、卡特洛(Carteolol)、萘丁諾(Levobunolol)、貝他舒洛(Betaxolol)、尼普地洛(Nipradilol)或苯呋洛爾(Befunolol);[3]如上述[1]或[2]所述之劑,其中,該β阻斷藥為滴目露;[4]如上述[1]至[3]中任一項所述之劑,其係將β阻斷藥或其藥學上容許之鹽與4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯各別或同時投予者;[5]一種用以治療青光眼或高眼壓症的醫藥組成物,係將4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯與β阻斷藥或其藥學上容許之鹽組合並投予;
[6]如上述[5]所述之醫藥組成物,其中,該β阻斷藥為滴目露、卡特洛、萘丁諾、貝他舒洛、尼普地洛或苯呋洛爾;[7]如上述[5]或[6]所述之醫藥組成物,其中,該β阻斷藥為滴目露;[8]如上述[5]至[7]中任一項所述之醫藥組成物,其中,該醫藥組成物為點眼劑或眼軟膏;[9]如上述[5]至[8]中任一項所述之醫藥組成物,其中,該醫藥組成物為複方劑;[10]一種青光眼或高眼壓症之治療方法,為以將有效量之4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯與β阻斷藥或其藥學上容許之鹽組合,並對必須治療青光眼或高眼壓症的病患各別或同時投予;[11]一種青光眼或高眼壓症的治療方法,為對必須治療青光眼或高眼壓症之病患投予有效量之4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯,該方法更包含投予有效量之β阻斷藥或其藥學上容許之鹽;[12]一種4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯,係與β阻斷藥或其藥學上容許之鹽組合,並且用於治療青光眼或高眼壓症;[13]一種4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯的
用途,係用以製造青光眼或高眼壓症治療劑,並且與β阻斷藥或其藥學上容許之鹽組合投予等實施態樣。
相較於各藥劑單劑投予時,本發明之組合具有增強眼壓降低作用且持續眼壓降低作用之效果,故作為青光眼治療劑為有用者。
(1)FP促效藥
用於本發明之組合之FP促效藥之一態樣,係列舉記載於國際公開第2011/013651號之下述式表示者。
其為4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯。
又,FP促效藥之另一態樣可列舉記載於國際公開第2011/013651號之一般式(I)表示之化合物、其鹽、其溶劑化物或其前驅藥。
(式中,所有符號與記載於國際公開第2011/013651號者同意義)
於本發明,若無特別說明,包含所有的異構物。例如,於烷基包含直鏈及支鏈者。又,於雙鍵、環、稠環之幾何異構物(E體、Z體、順式體、反式體)、由不對稱碳的存在等所產生之光學異構物(R、S體、α、β配置、對映體、非對映體)、具有旋光性之光學活性體(D、L、d、l體)、藉由層析分離所產生之極性體(高極性體、低極性體)、平衡化合物、旋轉異構物、該等任意比例之混合物、外消旋混合物皆包含於本發明中。又,本發明亦包含全部藉由互變異構物所產生之異構物。
又,本發明中之光學異構物不僅為100%純粹者,亦可包含未達50%之其他光學異構物。
化合物A可依照國際公開第2011/013651號中記載之實施例1→實施例2→實施例3→實施例4→實施例5→實施例6→實施例7→實施例8→實施例9→實施例10(1)→實施例11→實施例12→實施例13→實施例14→實施例15→實施例16(25)製造之。
本發明之組合中所使用之化合物A之投予量,係依據年齡、體重、症狀、治療效果、投予方法、處理時間等而異,例如若為點眼劑,每一成人每次將較佳為0.000001至5%(w/v),更佳為0.00001至0.05%(w/v)濃度者以1次量為1至數滴,1日1至數次(例如1至8次)點眼即可。又,若為眼軟膏,將較佳為0.000001至5%(w/w),更佳為0.00001至0.05%(w/w)濃度者以1日1至數次(例如1至4次)塗抹即可。
(2)β阻斷藥
於本發明中,β阻斷藥只要是遮斷交感神經之腎上腺素受體中之β-腎上腺素受體、β 1、β 2及β 3各受體中之任一種,且可用於治療青光眼之藥劑,則無特別限制,可列舉例如滴目露(timolol)、卡特洛(certeolol)、萘丁諾(levobunolol)、貝他舒洛(betaxolol)、尼普地洛(nipradilol)、苯呋洛爾(befunolol)或該等之藥學上容許之鹽。其中,較佳為替莫洛馬來酸鹽。
本發明之組合中使用之β阻斷藥之投予量,係依據年齡、體重、症狀、治療效果、投予方法、處理時間等而異,可應用作為醫藥品所核准製造之用量或低於該用量之用量。就具體之投予量而言,若為滴目露,可列舉為0.1至0.5%(w/v),較佳為0.25至0.5%(w/v)。若為卡特洛,可列舉為0.1至2%(w/v),較佳為1至2%(w/v)。若為萘丁諾,可列舉為0.1至0.5%(w/v),較佳為0.25至0.5%(w/v)。若為貝他舒洛,可列舉為0.1至0.5%(w/v),較佳為0.25至0.5%(w/v)。若為尼普地洛,可列舉為0.1至0.25%(w/v),較佳為0.25%(w/v)。若為苯呋洛爾,可列舉為0.1至0.25%(w/v),較佳為0.25%(w/v)。
於本發明,鹽以藥學上容許之鹽為較佳,或以水溶性者為較佳。藥學上容許之鹽可列舉:鹼金屬(鉀、鈉等)之鹽、鹼土金屬(鈣、鎂等)之鹽、銨鹽、藥學上容許之有機胺(四甲基銨、三乙胺、甲胺、二甲胺、環戊胺、苯甲胺、苯乙胺、哌啶、單乙醇胺、二乙醇胺、三(羥基甲基)胺基甲烷、離胺酸、精胺酸、N-甲基-D-麩胺酸等)之鹽、酸加成物鹽(無機酸鹽(鹽酸鹽、氫溴酸鹽、氫碘酸鹽、硫酸鹽、磷酸鹽、硝酸鹽等)、有機酸鹽(乙酸鹽、三氟乙酸鹽、乳酸鹽、酒石酸鹽、草酸鹽、富馬酸鹽、馬來酸鹽、苯甲酸鹽、檸檬酸鹽、甲磺酸鹽、乙磺酸鹽、苯磺酸鹽、甲苯磺酸鹽、羥乙磺酸鹽、葡糖醛酸鹽、葡糖酸鹽等)等)等。
上述之β阻斷藥皆為已上市之化合物,故為毒性非常低,可安全係使用為醫藥品。
本發明之組合係為了用於治療青光眼或高眼壓症,FP促效藥及β阻斷藥以適合治療該疾患之劑形,例如點眼劑、眼軟膏等較佳,亦可各個為各別之劑形。又,本發明之組合亦可為各別之製劑,若考慮到投藥之順從性,較佳為將兩劑以適當之份量含有之複方劑,例如複方點眼劑、複方眼軟膏。
於本發明之組合中,將FP促效藥及β阻斷藥以各別之製劑使用時,包含同時投予及藉由時間差進行之投予。又,藉由時間差進行之投予係指將FP促效藥及β阻斷藥於一定之時間各自投予,其投予順序可先投予FP促效藥再投予β阻斷藥,亦可先投予β阻斷藥再投予FP促效藥。
本發明組合所使用之點眼劑、眼軟膏可使用泛用的技術進行製劑化。例如,若為點眼劑,可適當地配合等張化劑、緩衝劑、pH調節劑、可溶化劑、增黏劑、穩定化劑、保存劑等作為添加物。又,藉由添加pH調節劑、增黏劑、分散劑等將藥物懸濁化,亦可獲得穩定之點眼劑。
[毒性]
本發明之組合之毒性係非常低者,可安全地使用為醫藥品。
[於醫藥品之應用]
藉由本發明之組合進行治療之疾患之一態樣,可列舉青光眼、高眼壓症。青光眼可列舉例如急性隅角閉鎖性青光眼、慢性隅角閉鎖性青光眼、續發隅角閉鎖性青光眼、原發隅角開放性青光眼、續發隅角開放性青光眼、先天性青光眼、正常眼壓青光眼、房水產生過多青光眼。
於本發明中,本發明之組合為了(1)補齊及/或增強治療效果、(2)改善動態/吸收、降低投予量及/或(3)減輕副作用,可再與其他之青光眼治療劑組合投予。
於本發明中,其他之青光眼治療劑只要是眾所皆知者即可,可列舉例如:交感神經促效藥(α 2促效藥:例如,鹽酸阿可樂定(Apraclonidine HCl)等、β 2促效藥:例如,鹽酸地匹福林(Dipivefrin HCl)等)、副交感神經促效藥(例如,鹽酸毛果芸香(Pilocarpine HCl)、卡巴膽鹼(Carbachol)、地美溴銨(Demecarium)、二乙氧磷醯膽鹼(Echothiophate)或溴化新斯狄格明(Neostigmine bromide)等)、交感神經抑制藥(α 1阻斷藥:例如,鹽酸布那唑嗪(Bunazosin HCl)等)、前列腺素系藥物(例如,烏諾前列腺酮異丙酯(Isopropyl Unoprostone)、拉坦前列素、比馬前列素(Bimatoprost)、曲伏前
列素(Travoprost)、EP2促效藥、EP4促效藥或DP促效藥等)、碳酸酐酶抑制劑(例如,乙醯唑胺(Acetazolamide)、雙氯磺醯胺(Diclofenamide)、甲氮醯胺(Methazolamide)、鹽酸多佐胺(Dorzolamide HCl)或布林佐胺(Brinzolamide)等)、高張滲透壓藥(例如,甘油、甘油及果糖之複方製劑或異山梨酯(Isosorbide)等)、ROCK(Rho-kinase)阻礙藥(例如Y-27632等)、NMDA拮抗藥。
以下,顯示實施例對本發明進行具體的說明,惟,本發明不限定於該等例。
使用4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯(化合物A)。化合物A可藉由眾所皆知之方法,例如,依照國際公開第2011/013651號中記載之實施例1→實施例2→實施例3→實施例4→實施例5→實施例6→實施例7→實施例8→實施例9→實施例10(1)→實施例11→實施例12→實施例13→實施例14→實施例15→實施例16(25)製造之。
生物學的實施例1:眼壓降低作用
使用化合物A及β阻斷藥作為受測物質。化合物A使用介質(含有0.3w/v%檸檬酸鈉、0.5w/v%聚山梨醇酯80及0.8w/v%氯化鈉之水溶液)調製成3μg/mL之溶液。使用滴目露(商品名:第莫普洛(Timoptol)(註冊商標)0.5%點眼液,參天製藥(股)公司製造)作為β阻斷藥。
於預先經充分的馴服之雄性狗(TOYO Beagle,使用開始時為16至42個月齡),於投予介質及受測物質約1小時前測定兩眼之眼壓,作為點眼前的眼壓值。之後,於處置眼將受測物質或介質各點眼投予30μL,於投予約2、4、6、8、24小時後測定兩眼之眼壓。眼壓係將局部麻醉劑之0.4%鹽酸奧布卡因(Oxybuprocaine HCl)(倍樂視(Benoxil)(註冊商標)點眼液0.4%、參天製藥(股)公司製造)點眼,於局部麻醉下以空壓壓平式眼壓計(Model30 Classic、Reichert公司製造)測定之。測定進行至獲得連續3次穩定之值為止(連續獲得之測定值之差在0.5mmHg以內)。將獲得之3次測定值之平均值作為眼壓值(mmHg),表示至小數點以下第1位。
將從受測物質及介質投予前之眼壓值扣除各測定時間之眼壓值之值作為眼壓降低幅度,於各測定時間,將各個體眼壓降低幅度之平均值作為平均眼壓降低幅度。於各測定時間中之平均眼壓降低幅度中,將最大值作為最大眼壓降低幅度。又,投予24小時後之平均眼壓降低幅度作為投予24小時後之眼壓降低幅度。將其結果示於表1。此外,於群名中,有2個藥劑名時係指投予順序,例如化合物A-滴目露群,係指於同眼先投予化合物A,之後再投予滴目露。
由其結果可知,化合物A及滴目露的併用,係與投予順序無關,並且相較於各單劑,顯示較強的眼壓降低作用。又,化合物A及滴目露的併用,係至投予24小時後仍觀察到持續之眼壓降低作用,進一步可知,相較於各單劑,,發揮最大眼壓降低作用之時間亦有變長的效果。
本發明之組合係發揮顯著的眼壓降低作用,故於治療青光眼或高眼壓症時為有用者。
Claims (6)
- 一種青光眼或高眼壓症之治療劑,係含有FP促效藥作為有效成分,並且該FP促效藥係與滴目露或其藥學上容許之鹽組合並投予,上述FP促效藥為4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯。
- 如申請專利範圍第1項所述之劑,其係將滴目露或其藥學上容許之鹽與4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯各別或同時投予者。
- 一種用於治療青光眼或高眼壓症之醫藥組成物,其中,4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯與滴目露或其藥學上容許之鹽係被組合並投予。
- 如申請專利範圍第3項所述之醫藥組成物,其為點眼劑或眼軟膏。
- 如申請專利範圍第3項或第4項所述之醫藥組成物,其為複方劑。
- 一種4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-二氟苯氧基)-3-羥基-1-丁烯-1-基]-7-羥基八氫-2H-環戊并[b]噁庚因-3-基}丁酸2-丙酯之用途,其係用以製造青光眼或高眼壓症治療劑,並且與滴目露或其藥學上容許之鹽組合並投予。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017244573 | 2017-12-21 | ||
JP2017-244573 | 2017-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201934542A TW201934542A (zh) | 2019-09-01 |
TWI809021B true TWI809021B (zh) | 2023-07-21 |
Family
ID=66993519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107146169A TWI809021B (zh) | 2017-12-21 | 2018-12-20 | 含有FP促效藥及β阻斷藥的青光眼治療劑 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210085636A1 (zh) |
EP (1) | EP3730137B1 (zh) |
JP (1) | JP7247894B2 (zh) |
KR (1) | KR20200102435A (zh) |
CN (1) | CN111479567B (zh) |
AU (1) | AU2018390274C1 (zh) |
BR (1) | BR112020012521A2 (zh) |
CA (1) | CA3085747A1 (zh) |
EA (1) | EA202091523A1 (zh) |
ES (1) | ES2978499T3 (zh) |
MX (1) | MX2020006429A (zh) |
PH (1) | PH12020550862A1 (zh) |
SG (1) | SG11202005620QA (zh) |
TW (1) | TWI809021B (zh) |
WO (1) | WO2019124523A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023204297A1 (ja) * | 2022-04-22 | 2023-10-26 | 参天製薬株式会社 | セペタプロストを含有する眼科用組成物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2460801T3 (pl) * | 2009-07-28 | 2014-11-28 | Ono Pharmaceutical Co | Związek bicykliczny i jego zastosowanie do celów medycznych |
-
2018
- 2018-12-20 BR BR112020012521-0A patent/BR112020012521A2/pt unknown
- 2018-12-20 TW TW107146169A patent/TWI809021B/zh active
- 2018-12-20 CN CN201880080852.2A patent/CN111479567B/zh active Active
- 2018-12-20 SG SG11202005620QA patent/SG11202005620QA/en unknown
- 2018-12-20 AU AU2018390274A patent/AU2018390274C1/en active Active
- 2018-12-20 CA CA3085747A patent/CA3085747A1/en active Pending
- 2018-12-20 MX MX2020006429A patent/MX2020006429A/es unknown
- 2018-12-20 ES ES18891086T patent/ES2978499T3/es active Active
- 2018-12-20 EP EP18891086.3A patent/EP3730137B1/en active Active
- 2018-12-20 EA EA202091523A patent/EA202091523A1/ru unknown
- 2018-12-20 US US16/954,416 patent/US20210085636A1/en active Pending
- 2018-12-20 WO PCT/JP2018/047102 patent/WO2019124523A1/ja unknown
- 2018-12-20 JP JP2019560578A patent/JP7247894B2/ja active Active
- 2018-12-20 KR KR1020207016945A patent/KR20200102435A/ko not_active Application Discontinuation
-
2020
- 2020-06-11 PH PH12020550862A patent/PH12020550862A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2018390274C1 (en) | 2024-02-29 |
MX2020006429A (es) | 2020-09-17 |
SG11202005620QA (en) | 2020-07-29 |
US20210085636A1 (en) | 2021-03-25 |
AU2018390274A1 (en) | 2020-07-02 |
EA202091523A1 (ru) | 2020-09-10 |
ES2978499T3 (es) | 2024-09-13 |
EP3730137A4 (en) | 2021-02-24 |
WO2019124523A1 (ja) | 2019-06-27 |
JPWO2019124523A1 (ja) | 2020-12-10 |
CN111479567B (zh) | 2023-05-23 |
EP3730137B1 (en) | 2024-03-20 |
CN111479567A (zh) | 2020-07-31 |
KR20200102435A (ko) | 2020-08-31 |
TW201934542A (zh) | 2019-09-01 |
JP7247894B2 (ja) | 2023-03-29 |
EP3730137A1 (en) | 2020-10-28 |
AU2018390274B2 (en) | 2023-02-02 |
BR112020012521A2 (pt) | 2020-11-24 |
PH12020550862A1 (en) | 2021-05-17 |
CA3085747A1 (en) | 2019-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5174777B2 (ja) | Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 | |
JP4934653B2 (ja) | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 | |
US10702511B2 (en) | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | |
JP4933897B2 (ja) | 眼内移行性促進水性点眼剤 | |
US20140018350A1 (en) | Combination of sulfonamide compound and tafluprost | |
JP4482726B2 (ja) | Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 | |
US11331311B2 (en) | Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound | |
JP6934581B2 (ja) | エピナスチン又はその塩を含有する水性医薬組成物 | |
TWI809021B (zh) | 含有FP促效藥及β阻斷藥的青光眼治療劑 | |
JP2012250951A (ja) | アデノシン誘導体とプロスタグランジン類とβ受容体遮断薬の組合せ剤 | |
KR20200103719A (ko) | 피리딜아미노아세트산 화합물을 함유하는 의약 제제 | |
JP6963651B2 (ja) | エピナスチン又はその塩を含有する水性組成物 | |
JP2005047909A (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
JP2003292442A (ja) | ブナゾシンとプロスタグランジン類からなる緑内障治療剤 | |
JP2012250949A (ja) | アデノシン誘導体と炭酸脱水酵素阻害剤とβ受容体遮断薬の組合せ剤 | |
JP2012250953A (ja) | アデノシン誘導体とα2受容体作動薬の組合せ剤 | |
EA043581B1 (ru) | ТЕРАПЕВТИЧЕСКИЙ АГЕНТ ДЛЯ ЛЕЧЕНИЯ ГЛАУКОМЫ, СОДЕРЖАЩИЙ АГОНИСТ FP-РЕЦЕПТОРОВ И β-БЛОКАТОР | |
JP7118579B1 (ja) | エピナスチン又はその塩を含有する水性組成物 | |
JP2012250947A (ja) | アデノシン誘導体とβ受容体遮断薬の組合せ剤 | |
JP2012250950A (ja) | アデノシン誘導体とプロスタグランジン類の組合せ剤 | |
JP2012250952A (ja) | アデノシン誘導体とRhoキナーゼ阻害剤の組合せ剤 | |
JP2012250948A (ja) | アデノシン誘導体と炭酸脱水酵素阻害剤の組合せ剤 |